Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 4/25/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Jan Schellens?

Jan Hm Schellens

Senior Groepsleider Klinisch Specialist

NKI-AVL

Direct Phone: +31 ** *** ****direct phone

Email: j***@***.nl

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

NKI-AVL

Background Information

Employment History

Section Editor

The Oncologist


Section Editor

AlphaMed Press


Affiliations

Dutch Medicines Evaluation Board MEB

Board Member


Cme Online

Board Member


Education

M.D.

The Netherlands Cancer Institute


Web References(29 Total References)


San Antonio Breast Cancer Symposium: Faculty - Faculty

www.sabcs.org [cached]

Jan H.M. Schellens, MD, PhD
Head, Department of Clinical Pharmacology The Netherlands Cancer Institute Dr. Schellens is a board certified medical oncologist and clinical pharmacologist with basic training in chemistry and teaches oncology and clinical pharmacology at Utrecht University, Netherlands. He is head of the department of Clinical Pharmacology at the Netherlands Cancer Institute, involved in translational research and early clinical studies. Dr. Schellens is a member of the Dutch Medicines Evaluation Board MEB, part of the EMA and Chairperson Scientific Advisory Group Oncology (SAG-Oncology to the EMA).


ZIOPHARM Oncology | Patient and Provider Access

www.ziopharm.com [cached]

Jan Schellens - Investigator+301-20-512-2569+301-20-512-2679 (f)j.schellens@nki.nl


www.atthelimits.org

Professor Jan Schellens
Head of the Division of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands


fip.org

Jan Schellens (The Netherlands Cancer Institute, The Netherlands)


Translational research: 4 ways to fix clinical trials | Clinuity

clinuity.com [cached]

A similar union of four institutions is in the works in the Netherlands, says Jan Schellens, an oncologist and pharmacologist at the Netherlands Cancer Institute in Amsterdam.
About one-quarter of the molecules entering clinical trials fail because of "poor pharmacology", says Schellens. The drug may not be readily absorbed, for example, or may not reach its target organ. With a simple test in humans, he says, "you could kill that drug much earlier, before you have invested so much time and money". Few, says Schellens, plan so far ahead.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory